Ipsen (Euronext: IPN; ADR: IPSEY) today announced that Lonza has successfully re-manufactured the active ingredient of Increlex® (mecasermin [rDNA origin] Injection). The European Medicines Agency (EMA) has been informed that Ipsen is preparing for the resupply of Increlex® in the European Union (EU).
Help employers find you! Check out all the jobs and post your resume.
